Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 15-26

  Arteaga, Carlos L ^a   Khuri, Fadlo ^a   Krystal, Geoffrey ^a   Sebti, Said ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Division of Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CELL PROTEIN; ERLOTINIB; GEFITINIB; GUANOSINE TRIPHOSPHATASE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PELITINIB; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; SU 5259; TRANSCRIPTION FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0036121207     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31524     Document Type: Article

References (94)

1. Signaling - 2000 and beyond
2. Untangling the ErbB signalling network
3. Specificity within the EGF family/ErbB receptor family signaling network
4. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
5. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
6. Transforming growth factor-α, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits
7. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes
8. Trans-activation of the epidermal growth factor receptor gene by the hepatitis B virus X-gene product
9. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
10. Epidermal growth factor-related peptides and their receptors in human malignancies
11. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
12. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
13. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
14. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer
15. The epidermal growth factor receptor and its inhibition in cancer therapy
16. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
17. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
18. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
19. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation, and induces apoptosis in human squamous cell carcinoma HN5
20. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells
21. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
22. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects
23. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous lung carcinoma
24. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
25. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
26. Development of inhibitors for protein tyrosine kinases
27. Tyrosine kinase inhibition: An approach to drug development
28. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
29. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
30. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
31. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline and 4-(phenylamino) pyrido
32. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD158780 and a new irreversible inhibitor PD183805
33. ZD1839 ('Iressa') as an anti-cancer agent
34. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
35. Combinatorial chemoprevention of intestinal neoplasia
36. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo
37. PKI-166 modulates proliferation, apoptosis and tumor growth of ERBB1/2 overexpressing cells
38. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
39. Combination of EGFR, HER-2/neu, and HER- 3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family member
40. Structural alterations of the epidermal growth factor receptor gene in human gliomas
41. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
42. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
43. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
44. Rho family proteins and Ras transformation: The RHOad less traveled gets congested
45. Ras genes
46. Regulators and effectors of ras proteins
47. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients
48. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung
49. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
50. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
51. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy
52. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
53. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor
54. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
55. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
56. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
57. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
58. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
59. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
60. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase
61. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility
62. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
63. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
64. Regulation of Ras-related RhoB protein expression during the cell cycle
65. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
66. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
67. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
68. Activation of Racl, RhoA, and mitogen-activated protein kinases is required for Ras transformation
69. A role for Rho in Ras transformation
70. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
71. Post-translational modifications of p21rho proteins
72. Farnesyltransferase inhibitors and cancer treatment: Targeting simply ras?
73. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice
74. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck
75. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
76. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer
77. Human protooncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
78. Steel factor and c-kit protooncogene: Genetic lessons in signal transduction
79. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer
80. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines
81. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts
82. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene
83. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins
84. Lysophosphatidic acid-depleted serum, hepatocyte growth factor, and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway
85. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
86. Inhibition of the Abl protein-tyrosine kinas in vitro and in vivo by a 2-phenylaminopyrimidine derivative
87. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
88. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
89. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
90. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCK-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
91. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
92. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
93. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
94. Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors